PMID- 23016535
OWN - NLM
STAT- MEDLINE
DCOM- 20130802
LR  - 20211021
IS  - 1931-8405 (Electronic)
IS  - 0889-2229 (Print)
IS  - 0889-2229 (Linking)
VI  - 29
IP  - 3
DP  - 2013 Mar
TI  - Long-term efficacy and safety of atazanavir/ritonavir treatment in a real-life 
      cohort of treatment-experienced patients with HIV type 1 infection.
PG  - 564-73
AB  - Atazanavir-based regimens have established efficacy and safety in both 
      antiretroviral (ARV)-naive and -experienced patients. However, data evaluating 
      effectiveness beyond 2 years is sparse. Therefore, we assessed the long-term 
      outcomes of ritonavir-boosted atazanavir (ATV/r)-containing regimens in 
      ARV-experienced patients in a clinical setting in a noncomparative, 
      retrospective, observational study collecting data from three European HIV 
      databases on ARV-experienced adults with HIV-1 infection starting an ATV/r-based 
      regimen. Data were extracted every 6 months (maximum follow-up 5 years). Primary 
      outcome was the proportion of patients remaining on ATV/r by baseline HIV-1 RNA 
      (<500 or >/=500 copies/ml). Secondary outcomes included time to virologic failure, 
      reasons for discontinuation, and long-term safety profile. The duration of 
      treatment and time to virologic failure were analyzed using the Kaplan-Meier 
      method. Data were analyzed for 1,294 ARV-experienced patients (male 74%; mean ART 
      exposure 5.7 years). After 3 years, 56% (95% CI: 52%, 60%) of patients with 
      baseline HIV-1 RNA <500 copies/ml and 53% (95% CI: 49%, 58%) of those with HIV-1 
      RNA >/=500 copies/ml remained on ATV/r. After 3 years, 75% (95% CI: 69%, 80%) of 
      patients with baseline HIV-1 RNA <50 copies/ml remained suppressed and 51% (95% 
      CI: 47%, 55%) of those with baseline HIV-1 RNA >/=50 copies/ml achieved and 
      maintained virologic suppression. Although adverse events (AEs) were the main 
      known reason for discontinuation, no unexpected AEs were observed. In a real-life 
      setting ATV/r-based regimens demonstrated sustained virologic suppression in 
      ARV-experienced patients. After long-term therapy the majority of patients 
      remained on treatment and no unexpected AEs were observed.
FAU - Jansen, Klaus
AU  - Jansen K
AD  - Competence Network for HIV/AIDS, Ruhr-Universitat, Bochum, Germany. 
      klaus.jansen@klinikum-bochum.de
FAU - Sonnerborg, Anders
AU  - Sonnerborg A
FAU - Brockmeyer, Norbert
AU  - Brockmeyer N
FAU - Thalme, Anders
AU  - Thalme A
FAU - Svedhem, Veronica
AU  - Svedhem V
FAU - Dupke, Stephan
AU  - Dupke S
FAU - Eychenne, Jean-Luc
AU  - Eychenne JL
FAU - Nakonz, Tina
AU  - Nakonz T
FAU - Jimenez-Exposito, Maria Jesus
AU  - Jimenez-Exposito MJ
FAU - Pugliese, Pascal
AU  - Pugliese P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121127
PL  - United States
TA  - AIDS Res Hum Retroviruses
JT  - AIDS research and human retroviruses
JID - 8709376
RN  - 0 (Anti-HIV Agents)
RN  - 0 (Oligopeptides)
RN  - 0 (Pyridines)
RN  - 0 (RNA, Viral)
RN  - 4MT4VIE29P (Atazanavir Sulfate)
RN  - O3J8G9O825 (Ritonavir)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-HIV Agents/*administration & dosage/adverse effects
MH  - Atazanavir Sulfate
MH  - Cohort Studies
MH  - Data Collection/methods
MH  - Databases, Factual
MH  - Europe
MH  - Female
MH  - HIV Infections/*drug therapy/virology
MH  - HIV-1/*isolation & purification
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Oligopeptides/*administration & dosage/adverse effects
MH  - Pyridines/*administration & dosage/adverse effects
MH  - RNA, Viral/blood
MH  - Retrospective Studies
MH  - Ritonavir/*administration & dosage/adverse effects
MH  - Treatment Outcome
MH  - Viral Load
MH  - Young Adult
PMC - PMC3698683
EDAT- 2012/09/29 06:00
MHDA- 2013/08/03 06:00
PMCR- 2013/03/01
CRDT- 2012/09/29 06:00
PHST- 2012/09/29 06:00 [entrez]
PHST- 2012/09/29 06:00 [pubmed]
PHST- 2013/08/03 06:00 [medline]
PHST- 2013/03/01 00:00 [pmc-release]
AID - 10.1089/aid.2012.0092 [pii]
AID - 10.1089/aid.2012.0092 [doi]
PST - ppublish
SO  - AIDS Res Hum Retroviruses. 2013 Mar;29(3):564-73. doi: 10.1089/aid.2012.0092. 
      Epub 2012 Nov 27.